BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced new novel Locked Nucleic Acid (LNA) programs directed against, the Androgen receptor (AR) and Phosphoinositide 3-kinase (PI3K/Akt). These targets are linked to a broad spectrum of cancers. Enzon has licensed eight novel LNA targets from Santaris Pharma A/S.
